Core Viewpoint - The approval of Ryaltris (GSP301NS) by the National Medical Products Administration (NMPA) marks a significant milestone for the company in the respiratory and critical care sector, providing a new treatment option for allergic rhinitis in China [1][2] Group 1: Product Development and Approval - Ryaltris is a novel combination nasal spray that combines an antihistamine and a corticosteroid, approved for treating moderate to severe seasonal allergic rhinitis in adults and children aged 6 and above [1] - The product received FDA approval in January 2022 and has been successfully launched in multiple countries, demonstrating strong sales performance and market potential [1] - The Phase III clinical trial (GSP301-308) involved 535 patients and showed that Ryaltris outperformed single-agent controls in efficacy, safety, and pharmacokinetics [2] Group 2: Market Opportunity - China has one of the highest prevalence rates of allergic rhinitis globally, with approximately 17.6% of adults affected, translating to nearly 250 million people, including around 130 million with moderate to severe persistent allergic rhinitis [3] - Current treatment options in China primarily consist of single-agent formulations, indicating a significant unmet clinical need and a vast market opportunity for combination therapies like Ryaltris [3] Group 3: Strategic Focus - The respiratory and critical care sector is a core strategic area for the company, with a comprehensive product portfolio addressing various respiratory conditions [4] - The company is committed to innovation and has several products in development targeting unmet clinical needs, including sepsis and acute respiratory distress syndrome [4] - The company aims to enhance its product pipeline and industry position through a combination of independent research and global expansion strategies [5]

Core Viewpoint - The announcement by the company regarding the approval of its fluticasone propionate nasal spray marks a significant step in breaking the market monopoly of foreign products in the domestic allergic rhinitis treatment sector [2]. Group 1: Product Development and Market Position - The fluticasone propionate nasal spray is the first domestic generic product to be launched in China and has been included in the national medical insurance and essential drug lists [2]. - The company has established itself as one of the leading firms in the domestic market for allergic rhinitis treatments, with a comprehensive product pipeline [2]. - The respiratory and critical care segment generated approximately HKD 1.71 billion in revenue last year, reflecting a nearly 27% year-on-year growth [2]. Group 2: Future Development Strategy - The company plans to continue its strategy of independent research and global expansion, focusing on developing a comprehensive product cluster for chronic airway diseases and critical care [3].